secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001104659-22-069026
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics announces 2022 annual meeting voting results
-----------------------------------------------------------------------

- Three Class II directors elected: Ali Behbahani (18.2M for), Garry Menzel (18.6M for), Samarth Kulkarni (21.8M for).
- PricewaterhouseCoopers LLP ratified as auditor for FY2022 with 30.1M for, 14k against, 55k abstain.
- Quorum of 30.2M shares out of 36.3M outstanding was present at the June 7, 2022 virtual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922069026/0001104659-22-069026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922069026/tm2217931d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-069026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer